Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 907-914

  Nicolini, Franck E ^a   Masszi, Tamas ^b   Shen, Zhixiang ^c   Gallagher, Neil J ^d   Jootar, Saengsuree ^e   Powell, Bayard L ^f   Dorlhiac Llacer, Pedro Enrique ^g   Zheng, Ming ^d   Szczudlo, Tomasz ^d   Turkina, Anna ^h  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Szent Laszlo Hospital   (Hungary)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d NOVARTIS PHARMA AG   (Switzerland)

^e MAHIDOL UNIVERSITY   (Thailand)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

Author keywords

accelerated phase; blast crisis; CML; ENACT; nilotinib

Indexed keywords

BILIRUBIN; BUSULFAN; DASATINIB; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; BLAST CELL CRISIS; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLAST CRISIS; COMPASSIONATE USE TRIALS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACCELERATED PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859972409     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.627480     Document Type: Article

References (17)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.
2. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identifi ed by quinacrine fl uorescence and Giemsa staining. Nature 1973;243:290-293.
3. Agis H, Sotlar K, Valent P, et al. Ph-chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis. Leuk Res 2005;29:1227-1232. (Pubitemid 41169242)
4. Shtivelman E, Lifshitz B, Gale RP, et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550-554. (Pubitemid 15021190)
5. Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins bind directly to activators of the ras signalling pathway. EMBO J 1994;13:764-773. (Pubitemid 24057507)
6. Gordon MY, Dowding CR, Riley GP, et al. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987;328:342-344. (Pubitemid 17097654)
7. Bedi A, Zehnbauer BA, Barber JP, et al. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994;83:2038-2044. (Pubitemid 24112713)
8. Cortes J, O'D wyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;18:671-684. (Pubitemid 38969138)
9. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant bcr-Abl. Cancer Cell 2005;7:129-141. (Pubitemid 40248339)
10. Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is eff ective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141-1145.
11. le Coutre P, Giles F, Hochhaus A, et al. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. J Clin Oncol 2009;27(15 Suppl.): Abstract 7057.
12. Giles FJ, Kantarjian H, le Coutre PD, et al. Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib. J Clin Oncol 2010;28(15 Suppl.): Abstract 6510.
13. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-2259.
14. Nicolini FE, Turkina A, Shen ZX, et al. Expanding Nilotinib Access in Clinical Trials (ENACT): An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer 2011 Jul 5 [Epub ahead of print]
15. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinibresistant CML and philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-2551. (Pubitemid 43882350)
16. Chugh SS, Jui J, Gunson K, et al. Current burden of sudden cardiac death: Multiple source surveillance versus retrospective death certifi cate-based review in a large U.S. community. J Am Coll Cardiol 2004;44:1268-1275. (Pubitemid 39208884)
17. Kantarjian H, O'Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007;109:1556-1560. (Pubitemid 46603580)